Noxopharm spins off Nyrada pharma group
Metastatic cancer treatment biotech Noxopharm (ASX NOX) has successfully listed its Nyrada Inc spin off on the Australian Stock Exchange. Noxopharm, which is focusing on commercialising its Veyonda treatment for late-stage cancers, listed Nyrada to develop non-oncology drug prospects developed by the group. Nyrada is listed as a foreign company on the ASX through the…
Details